# US 2021/0340565 A1 · Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340565 A1
- Document ID: US20210340565A1
- Status: Published application
- Kind: A1
- Application number: 17/103,783
- Filed: 2020-11-24
- Published: 2021-11-04
- Earliest claimed: 2013-02-01
- Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite De Strasbourg; Cornell University; Universite Paris-Sud Xi; Assistance Publique-HôPitaux De Paris (Aphp)
- Applicants: Institut National De La Santé Et De La Recherche MéDicale (Inserm); Centre National De La Recherche Scientifique (Cnrs); Université De Strasbourg; Cornell University; Université Paris-Sud Xi; Assistance Publique - HôPitaux De Paris (Aphp)
- Inventors: Helene Monique PUCCIO; Patrick AUBOURG; Ronald G. CRYSTAL; Pierre BOUGNERES
- Web page: https://patentgrep.com/patent/US20210340565A1

## CPC

- C12N 15/86: Viral vectors
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/44: Oxidoreductases (1)
- A61K 48/0016: {wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 14/47: from mammals
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2750/14032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2750/14071: Demonstrated in vivo effect
- C12N 2750/14132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12Y 116/03001: Ferroxidase (1.16.3.1), i.e. ceruloplasmin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence of a gene that can restore energy failure. More particularly, the invention relates to a method for preventing or treating a cardiomyopathy associated with Friedreich ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a frataxin (FXN) encoding nucleic acid.

## Claims

### Claim 1

A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence of a gene that can restore energy failure.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the cardiomyopathy due to energy failure is a cardiomyopathy associated with Friedreich ataxia and the gene that can restore energy failure is the frataxin (FXN) encoding nucleic acid.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said FXN encoding nucleic acid encodes for the amino acid sequence SEQ ID NO:2.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the vector comprises the nucleic acid sequence SEQ ID NO:1.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the vector is selected from the group consisting of adenovirus, retrovirus, herpesvirus and Adeno-Associated Virus (AAV) vectors.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the vector is an AAV vector.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the AAV vector is an AAV1, AAV2, AAV3, AAV4, AAS, AAV6, AAV7, AAV8, AAV9, AAVrh10 vector or any AAV derived vector.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the AA V vector is an AA Vrh10 vector.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the vector is administered intracoronary or directly into the myocardium of the subject.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the vector is administered by intravenous injection.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

A method for reversing symptoms of cardiomyopathy associated with Friedreich ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a frataxin (FXN) encoding nucleic acid.

### Claim 14

A vector which comprises a nucleic acid sequence of a gene that can restore energy failure for use in treatment or prevention of cardiomyopathy due to energy failure in a subject in need thereof.

### Claim 15 (depends on 14)

A vector according to claim 14, wherein the vector comprises a frataxin (FXN) encoding nucleic acid.

### Claim 16 (depends on 14)

A vector according to claim 14, wherein the cardiomyopathy is a cardiomyopathy associated with Friedreich ataxia.

### Claim 17 (depends on 14)

A vector according to claim 14, wherein the vector is an AAVrh10 vector.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)
